Pancreatic Cancer Research

Clinical trialObsCompleted

CT Radiomic Features of Pancreatic Neuroendocrine Neoplasms

NCT03967951↗ ClinicalTrials.gov, retrieved 6 November 2026

Outcome
Finished, no results posted
Phase
Obs
Status
Completed
Study type
Observational
Start
23 March 2019
Expected end
6 May 2019
Enrollment
70 participants
Sites
2
Primary outcomes
Interobserver variability in delineating panNENs on CT
Sponsor
Other
Results posted
No
Last update
23 September 2026

These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

The aim of this study is to quantify inter-observer variability in delineating pancreatic neuroendocrine neoplasm (PanNEN) on Computerized Tomography (CT) images and its impact on radiomic features (RF), subsequently to this determination, to use CT texture analysis to predict, histological characteristics of PanNEN on CT scans.

Detailed description public domain (ClinicalTrials.gov)

CT imaging is the most widely used modality for studying radiomic features due to its ability to assess tissue density, shape, texture and size before, during and after therapy. To the best of the investigator's knowledge, the impact of inter-observer delineation variability on the reliability of CT RF for PanNEN patients, including Hounsfield unit (HU) values-, shape-, and texture-based features, has not yet been assessed. One this has been determined, an additional evaluation will be conducted to correlate the morphologically observed images with their histopathological characteristics. The ultimate potential objective of this research is to identify and predict characteristics of aggressiveness of PanNEN in CT scans.

Papers 2